摘要
新英格兰医学杂志于2007年5月21日在线发表了Nissen和Wolski关于文迪雅(马来酸罗格列酮)心血管危险的荟萃分析,掀起了一场震惊世界的文迪雅风暴。世界各大内分泌和糖尿病组织,美国、欧洲和中国等药物监督管理部门分别就Nissen和Wolski的文章发表声明。6月5日,该杂志又在线发表了Home等的评价罗格列酮对糖尿病心脏事件及血糖调节作用(RECORD)研究,并发表了3篇编者述评。6月26日,第67届美国糖尿病学会(ADA)年会又组织了文迪雅专题辩论会。本文就最近发表的相关文章和网上新闻作一综述,供读者参考。
The New England Journal of Medieine（NFAM） published on line the meta-analysis by Nissen and Wolski about the cardiovascular risk of Avandia on May 21,2007, sparked a worldwide Avandia storm. Endocrine and diabetes organization from different country and FDA, EMEA and SFDA released statements immediately as a response to Nissen and Wolski＇s meta-analysis. On June 5, NEJM published on line the RECORD study by Home et al, and three editorials were published at the same time. On June 26, ADA organized a symposium on the cardiovascular risk of Avandia. Here reviews the relationship between Avandia and the cardiovascular risk according to the published papers and the news released from the net.
出处
《国际内分泌代谢杂志》
2007年第4期217-222,共6页
International Journal of Endocrinology and Metabolism
关键词
罗格列酮
心血管疾病
糖尿病
Rosiglitazone
Cardiovascular diseases
Diabetes meUitus
